The Kidneys Under Chemical Pressure: PFAS and Renal Health
The kidneys—paired organs responsible for filtering blood, eliminating waste, and regulating fluid balance—are primary targets for PFAS accumulation due to their role in processing and excreting these compounds. PFAS are eliminated from the body primarily through the kidneys (for carboxylate PFAS) or through a combination of renal and biliary excretion (for sulfonate PFAS), meaning that renal tubular cells are continuously exposed to PFAS as the kidneys attempt to clear them from circulation. The concentration-dependent exposure of renal epithelial cells to PFAS during excretion creates the conditions for cumulative kidney toxicity over years and decades of exposure.
Mechanisms of PFAS Renal Toxicity
PFAS accumulate in renal proximal tubule cells—the workhorses of kidney filtration—where they are reabsorbed from the glomerular filtrate through organic anion transporter proteins (OATs). This reabsorption process, paradoxically intended to recapture filtered PFAS rather than excrete them, exposes proximal tubule cells to particularly high intracellular PFAS concentrations. Mitochondrial dysfunction, oxidative stress, and inhibition of fatty acid oxidation pathways in tubular cells have all been documented in cellular models of PFAS exposure, providing mechanistic plausibility for observed renal function impairments.
Glomerular filtration rate (GFR)—the clinical gold standard measure of kidney function—has been inversely associated with PFAS blood concentrations in several epidemiological studies. Lower estimated GFR at higher PFAS levels suggests that PFAS contributes to reduced kidney filtration capacity, potentially accelerating the natural age-related decline in renal function that affects all humans. For individuals with existing kidney disease, PFAS-associated functional impairment may represent a meaningful contribution to disease progression.
Epidemiological Evidence Across Populations
The C8 Health Project—providing the most detailed PFAS health data from any single exposed population—documented associations between PFOA exposure and diagnosed kidney disease in the West Virginia and Ohio communities near DuPont’s Washington Works facility. A panel of independent scientists reviewing C8 data found a “probable link” between PFOA and kidney cancer—a finding that influenced subsequent EPA risk assessments. Beyond the C8 cohort, NHANES-based analyses have found PFAS associations with markers of kidney injury including urinary albumin-creatinine ratio elevation, an early indicator of glomerular damage preceding overt kidney disease.
A 2020 study in the Journal of the American Society of Nephrology—using data from the Strong Heart Study, a prospective cohort of American Indian adults—found significant associations between multiple PFAS compounds and incident chronic kidney disease over a 10-year follow-up period. The American Indian populations studied have high rates of diabetes-related kidney disease, and PFAS exposure appeared to compound risk independently of diabetic nephropathy pathways.
Clinical and Dialysis Implications
For patients on dialysis—whose kidneys can no longer adequately filter blood—PFAS accumulation becomes a particular concern. Conventional hemodialysis using standard cellulose-based membranes provides limited PFAS removal, potentially allowing PFAS accumulation to continue even in dialysis-dependent patients. High-flux dialysis membranes and alternative dialysis modalities may offer somewhat better PFAS clearance, but systematic study of PFAS removal efficiency in dialysis patients is lacking. Nephrologists managing patients with high PFAS exposures may wish to consider this dimension of clinical care, and PFAS body burden reduction through dietary and water source modifications is particularly important for patients with diminished renal clearance capacity.